Established in 2007, Xi'an New Drug Evaluation and Research Center (XDER) is a contract research organization offering integrated preclinical services to the biotechnology and pharmaceutical industries, including 1) P III laboratory services, 2) Radioactive compounds DMPK (Whole-body Autoradiography), 3)DSI System.

 

Housed in the 50,000 sq. ft, state-of-the-art facility, XDER is in full compliance with SFDA GLP requirements. XDER seeks to provide an instrumental basis for drug discovery and an insight into designing in vivo efficacy studies. It utilizes cutting-age equipments and work closely with clients to develop an optimized experimental plan in accordance with well-defined standard operating procedures (SOPs). Its senior management team consists of Ph.D.s and MBAs with experience in pharmaceutical, biotechnology and international business practices.